Foghorn Therapeutics (FHTX) Accumulated Expenses (2019 - 2026)

Foghorn Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 7.28% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 7.28% YoY), while the FY2025 annual figure was $11.4 million, up 33.13% from the prior year.
• Accumulated Expenses was $6.9 million for Q1 2026 at Foghorn Therapeutics, down from $11.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.4 million in Q4 2025 to a low of $6.3 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $8.6 million across 5 years, with a median of $8.6 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 57.14% in 2022, then retreated 29.06% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $11.0 million in 2022, then dropped by 17.21% to $9.1 million in 2023, then decreased by 6.34% to $8.5 million in 2024, then surged by 33.13% to $11.4 million in 2025, then tumbled by 39.03% to $6.9 million in 2026.
• The last three Accumulated Expenses figures came in at $6.9 million (Q1 2026), $11.4 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.